The Globe and Mail

Stevanato Group Files Form 6-K With Q4 and FY 2025 Results Presentation

Stevanato Group ( (STVN)) has shared an update. On March 4, 2026, Stevanato Group filed a Form 6-K with the U.S. Securities and Exchange Commission, furnishing the investor presentation used for its ...
Hosted on MSN

Stevanato Group reiterates 2025 outlook, projects high-value solutions to reach up to 44% of revenue as biologics demand accelerates

Earnings Call Insights: Stevanato Group S.p.A. (STVN) Q3 2025 Franco Stevanato, CEO & Executive Chairman, reported "another solid quarter of financial results, driven by revenue growth, a record mix ...
WISH-TV

Mayor: Stevanato brings momentum for life sciences in Fishers

FISHERS, Ind. (Inside INdiana Business) — The mayor of Fishers says Italy-based Stevanato Group’s planned $145 million manufacturing plant is adding to a continued focus on the life sciences sector in ...
The Globe and Mail

Stevanato Group Posts 2025 Growth on High-Value Syringes and GLP‑1 Demand

Stevanato Group ( (STVN)) has provided an announcement. On March 4, 2026, Stevanato Group management reviewed fourth-quarter and full-year 2025 results, reporting 2025 revenue growth of 9% at constant ...